这个招募130例患者的I期已经完成招募了,希望尽快结束,然后启动III期
国内处于上市申请阶段的第三代 EGFR 抑制剂还有两款,艾力斯医药的伏美替尼和艾森生物的艾维替尼,...
(Prefilled syringe, PFS)、自动注射器(Autoinjector, AI)或小瓶(vial),应该是换了装药方式
Brief Summary:
This study will be a single-center, randomized, parallel, open-label, single dosing bridging study in healthy subjects to evaluate bioequivalence of two formulations of SHR-1314. Subjects will be randomly assigned to the Vials group, the PFS group at a ratio of 1:1